USFDA concludes inspection at Shilpa Medicare Hyderabad unit with zero observations
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-06-26 08:00 GMT | Update On 2024-06-26 08:00 GMT
Advertisement
Karnataka: Shilpa Medicare has announced that the US Food and Drug Administration (USFDA) has concluded the inspection at the Company's Bio Analytical Laboratory, Unit 7, Nacharam, Hyderabad, India with zero 483 observations and no discussion items.
The inspection was held from 26th February to 1st March 2024.
The Agency has concluded that this inspection has now been closed with the issuance of the Establishment Inspection Report (EIR). The facility is classified as “No Action Indicated” (NAI).
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.